Imprimis NJOF, LLC recalled 778 boxes of Dexamethasone Moxifloxacin intraocular injection on December 18, 2025. The recall stems from the presence of glass-like particles in the product. Consumers and healthcare providers should stop using the product immediately.
Presence of particulate matter - Glass like particles.
Consumers and healthcare providers should stop using this product immediately. Contact Imprimis NJOF, LLC or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is Dexamethasone Moxifloxacin, available in 1 mg/mL and 5 mg/mL concentrations, packaged in 1 mL pre-filled syringes. The lot numbers affected include 25MAY051 and 25AUG003, with expiration dates of June 26, 2026, and August 7, 2026, respectively.
The recall was issued due to the presence of particulate matter, specifically glass-like particles, which pose a serious health risk. The presence of these particles could lead to severe complications or adverse reactions when injected.
There are no reported injuries or deaths associated with this recall at this time. The recall is classified as Class II, indicating a potential for temporary or medically reversible health consequences.
Stop using the affected product immediately. Contact Imprimis NJOF, LLC or your healthcare provider for further guidance and instructions regarding the return of the product.
For more information, consumers can reach Imprimis NJOF, LLC directly. Visit the FDA recall page for additional details.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.